Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Novartis Stockpiling Priority Review Vouchers

Dec 19 2017

• By Derrick Gingery

Priority Review Voucher

Related Content

Novartis Takes Stock Of Ilaris For Gout Following FDA's Complete Response Letter

Aug 29 2011

Priority Review Voucher Sales Prices Level Off In 2017

Nov 27 2017

Novel Biologics Will Get Suffixes (Or At Least One Did)

Nov 16 2017

Best-In-Class Or First-In-Class: CGRP Inhibitors Line Up To Win The Migraine Market

May 09 2017

Novartis Back In AMD Game With ‘Potential Blockbuster’ Brolucizumab

Nov 12 2017

Novartis Floats 'Bold' Value-Based Reimbursement Idea In Migraine

Nov 13 2017

Novartis Aims Canakinumab At Targeted CV Patients

Nov 13 2017

Novartis Beats CAR-T Competitors To The Pricing Punch With Kymriah Approval

Aug 31 2017

Related Companies

Novartis AG

Ultragenyx Pharmaceutical Inc.

Amgen, Inc.

Teva Pharmaceutical Industries Ltd.

Additional Topics

Business Strategies Drug Review Strategy Regulation Rare Diseases BioPharmaceutical

More from Strategy

More from Business

Twitter feed RSS feed RSS feed

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.